Despite these insights, experimental validation and elucidation of the underpinning biological mechanisms have not been performed, and interventions governing the impact of HER2-low expression on the response to CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-low breast cancer remain elusive. This evidence concerns the gene ERBB2 and breast carcinoma.